RNA medicines – Talk Bio

Actionable Insights Powered by AI

Bristol Myers Squibb Enters In Vivo CAR-T Field with $1.5B Acquisition of Orbital Therapeutics

2 weeks ago talkbio0Tagged Acquisition, Autoimmune Diseases, Automobiles, Cell Therapy, immune system reprogramming, in vivo, Myers Squibb, NUSAP1 gene, Obstetric Delivery, Orbital Therapeutics, OTX-201, RNA medicines, RNA, Circular, T-cell therapy

Bristol Myers Squibb; Orbital Therapeutics; in vivo CAR T-cell therapy; autoimmune diseases; RNA medicines; OTX-201; cell therapy; acquisition; LNP delivery; circular RNA; immune system reprogramming

Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases

1 year ago talkbio0Tagged Biosciences, Biotechnology, Borealis, Kidney, Kidney Diseases, Novartis, RNA, RNA medicines, startup, Ventures, Versant, xRNA

Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.